Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

28, 2025 – The FDA has approved a new treatment for certain types of advanced breast cancer ... a monoclonal antibody, trastuzumab, that targets HER2 with the chemotherapy drug deruxtecan.

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients ... deruxtecan-nxki), the antibody-drug conjugate jointly developed by ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...